Last reviewed · How we verify
Topical Dapsone 5% Gel
Topical dapsone reduces inflammation and bacterial colonization in skin lesions through its antimicrobial and anti-inflammatory properties.
Topical dapsone reduces inflammation and bacterial colonization in skin lesions through its antimicrobial and anti-inflammatory properties. Used for Acne vulgaris, Rosacea, Other inflammatory skin conditions.
At a glance
| Generic name | Topical Dapsone 5% Gel |
|---|---|
| Sponsor | Memorial Sloan Kettering Cancer Center |
| Drug class | Sulfone antimicrobial |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
Dapsone is a sulfone antimicrobial agent that inhibits bacterial folate synthesis and possesses immunomodulatory effects that reduce neutrophilic inflammation. When formulated as a topical 5% gel, it delivers the drug directly to affected skin areas, minimizing systemic exposure while treating localized inflammatory and infectious skin conditions.
Approved indications
- Acne vulgaris
- Rosacea
- Other inflammatory skin conditions
Common side effects
- Local skin irritation
- Erythema
- Dryness
- Contact dermatitis
Key clinical trials
- Comparison of the Efficacy of Clindamycin Phosphate 1% Gel Versus Once-daily Dapsone 5% Gel in the Treatment of Moderate Acne Vulgaris (PHASE2)
- Effect of New Topical Preparation for Treatment of Acne Vulgaris (PHASE2)
- Use of Dapsone Gel, 5% for Treating Dermatitis Herpetiformis (PHASE4)
- Study to Determine and Compare the Tolerance and Irritation Potential of Topical Acne Medications (PHASE4)
- Study Comparing Test to Aczone 5% and Both to a Placebo Control in the Treatment of Acne Vulgaris (PHASE1)
- Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT (PHASE3)
- Trial of Dapsone 5.0% Gel in the Treatment of Acne Vulgaris (PHASE3)
- A Study Comparing Aczone® Plus Differin® Versus Duac® Plus Differin® in Patients With Severe Facial Acne (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |